Carl Firth | Chief Executive Officer
ASLAN Pharmaceuticals | Singapore

Dr Carl Firth is Founder and Chief Executive Officer of ASLAN Pharmaceuticals.

Prior to founding ASLAN, Carl was Head of Asia Healthcare at Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions. Prior to joining the banking industry, Carl worked for AstraZeneca across various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product Development, China.

Carl is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council. He is an independent director of Exploit Technologies, a commercialisation arm of Singapore’s Agency for Science, Technology and Research (A*STAR), which supports A*STAR in its efforts to transform the economy by driving innovation and commercialising its research outcomes.

Previously, Carl was an independent director of Hong Kong listed Uni-Bio Sciences, a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialisation of biopharmaceuticals for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017.

Carl is an Adjunct Professor at Duke-NUS Medical School. He has a PhD in Molecular Biology from Cambridge University (Trinity College), an Executive MBA from London Business School; and a BA in Molecular Biology from Cambridge University.